In Brief: Lilly's lispro insulin analog
Lilly's lispro insulin analog: NDA sent to FDA March 13 for lispro, tradenamed Humalog, as an injectable treatment for Type I diabetes. The NDA is based on data from more than 3,000 patients worldwide. Studies presented at the International Diabetes Federation Conference in November in Kobe, Japan show that "lispro injected immediately before the meal results in improved postprandial glucose control in comparison to" human regular insulin "given at least 30 minutes before the meal," according to an abstract of a 336-patient study...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth